riluzole has been researched along with Neoplasms in 6 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole was given at 100 mg PO BID in combination with sorafenib, beginning at 200 mg PO daily and escalating in 200 mg increments per level in 28-day cycles." | 3.30 | A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850. ( Aisner, J; Cerchio, R; Chan, N; Chen, S; Ganesan, S; Goodin, S; Gounder, M; Li, J; Lin, H; Malhotra, J; Marinaro, C; Mehnert, JM; Portal, DE; Shih, W; Silk, AW; Spencer, KR; Stein, MN, 2023) |
| "Riluzole has no negative effect on oxaliplatin antiproliferative capacity in human colorectal cancer cells and on its anticancer effect in a mouse model of colorectal cancer." | 1.48 | Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. ( Aissouni, Y; Authier, N; Balayssac, D; Barriere, DA; Busserolles, J; Eschalier, A; Giraudet, F; Kerckhove, N; Lamoine, S; Lazdunski, M; Lolignier, S; Meleine, M; Pereira, V; Poupon, L; Prival, L; Richard, D, 2018) |
| "Current cancer therapies are challenged by weakly soluble drugs and by drug combinations that exhibit non-uniform biodistribution and poor bioavailability." | 1.39 | Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy. ( Chen, S; Cui, M; Griffith, CK; Moghe, PV; Naczynski, DJ; Poventud-Fuentes, I; Roth, CM; Sheihet, L; Zevon, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Blyufer, A | 1 |
| Lhamo, S | 1 |
| Tam, C | 1 |
| Tariq, I | 1 |
| Thavornwatanayong, T | 1 |
| Mahajan, SS | 1 |
| Spencer, KR | 1 |
| Portal, DE | 1 |
| Aisner, J | 1 |
| Stein, MN | 1 |
| Malhotra, J | 1 |
| Shih, W | 1 |
| Chan, N | 1 |
| Silk, AW | 1 |
| Ganesan, S | 1 |
| Goodin, S | 1 |
| Gounder, M | 1 |
| Lin, H | 1 |
| Li, J | 1 |
| Cerchio, R | 1 |
| Marinaro, C | 1 |
| Chen, S | 2 |
| Mehnert, JM | 1 |
| Poupon, L | 1 |
| Lamoine, S | 1 |
| Pereira, V | 1 |
| Barriere, DA | 1 |
| Lolignier, S | 1 |
| Giraudet, F | 1 |
| Aissouni, Y | 1 |
| Meleine, M | 1 |
| Prival, L | 1 |
| Richard, D | 1 |
| Kerckhove, N | 1 |
| Authier, N | 1 |
| Balayssac, D | 1 |
| Eschalier, A | 1 |
| Lazdunski, M | 1 |
| Busserolles, J | 1 |
| Cui, M | 1 |
| Naczynski, DJ | 1 |
| Zevon, M | 1 |
| Griffith, CK | 1 |
| Sheihet, L | 1 |
| Poventud-Fuentes, I | 1 |
| Roth, CM | 1 |
| Moghe, PV | 1 |
2 reviews available for riluzole and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Riluzole: A neuroprotective drug with potential as a novel anti‑cancer agent (Review).
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Neopl | 2021 |
1 trial available for riluzole and Neoplasms
| Article | Year |
|---|---|
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Maximum Tolerated Dose; Neoplasms; Niacinami | 2023 |
3 other studies available for riluzole and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Depression; Humans; Male; Mice; Mice, | 2018 |
Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Collagenases; Curcumin; Drug Carriers; Human | 2013 |